The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 23 of the 36 sources its claims cite were checked for support.
Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis
Open accessAbstract
The apolipoprotein E ( APOE ) - ε4 allele is the strongest genetic risk factor for late-onset, sporadic Alzheimer's disease, likely increasing risk by altering amyloid-β (Aβ) accumulation. We recently demonstrated that the low-density lipoprotein receptor (LDLR) is a major apoE receptor in the brain that strongly regulates amyloid plaque deposition. In the current study, we sought to understand the mechanism by which LDLR regulates Aβ accumulation by altering Aβ clearance from brain interstitial fluid. We hypothesized that increasing LDLR levels enhances blood–brain barrier-mediated Aβ clearance, thus leading to reduced Aβ accumulation. Using the brain Aβ efflux index method, we found that blood–brain barrier-mediated clearance of exogenously administered Aβ is enhanced with LDLR overexpression. We next developed a method to directly assess the elimination of centrally derived, endogenous Aβ into the plasma of mice using an anti-Aβ antibody that prevents degradation of plasma Aβ, allowing its rate of appearance from the brain to be measured. Using this plasma Aβ accumulation technique, we found that LDLR overexpression enhances brain-to-blood Aβ transport. Together, our results suggest a unique mechanism by which LDLR regulates brain-to-blood Aβ clearance, which may serve as a useful therapeutic avenue in targeting Aβ clearance from the brain.
Overview
CoChat Summary
TL;DR
LDLR overexpression in mouse models increases blood–brain barrier-mediated clearance of Aβ from brain interstitial fluid to blood, reducing Aβ accumulation. The effect appears indirect, involving reduced apoE and LRP1 at the BBB.
Key findings
- In brain efflux index experiments, LDLR overexpression increased BBB-mediated Aβ clearance: BBB transport accounted for 66.9% of total Aβ clearance in TG vs. 36.3% in NTG, while brain retention was 27.8% vs. 58.6%; ISF bulk flow was similar (5.1% vs. 5.3%).
- In 10-mo PDAPP/LDLR mice, hippocampus and cortex had 2.7-fold and 4.8-fold less Aβ burden than PDAPP littermates; fibrillar amyloid burden was also reduced, and apoE levels were decreased 2.9-fold and 2.5-fold.
- Using anti-Aβ antibody HJ5.1 to stabilize plasma Aβ, the plasma appearance rate of CNS-derived human Aβ was faster in PD-TG than PD-NTG mice (92 ± 4.8 vs. 69 ± 6.9 pg·mL−1·min−1).
- Blocking LRP1 with an anti-LRP1 antibody attenuated the BBB component of Aβ clearance in LDLR-TG mice, suggesting LRP1 partly mediates the effect.
Methods
- Brain efflux index (BEI): 12 nM [125I]Aβ40 coinjected with [14C]inulin into brain ISF of 4–5 mo NTG and LDLR-TG mice; kinetic modeling estimated BBB transport, ISF bulk flow, and brain retention.
- Cross-bred LDLR-TG with PDAPP (APP-V717F) mice; measured Aβ burden, fibrillar amyloid, apoE, and ISF Aβ in 3–4 or 10 mo mice; in vivo microdialysis assessed ISF Aβ.
- Plasma accumulation: 250 μg HJ5.1 anti-Aβ antibody i.v., serial retro-orbital plasma samples 20–240 min, human Aβ quantified by immunoprecipitation/mass spectrometry; rates from linear regressions.
Limitations
- Stated: the BEI method uses a kinetic model that cannot perfectly describe complex BBB physiology, and rapid peripheral distribution of Aβ makes following radiolabeled Aβ into blood difficult.
- Stated: peripheral HJ5.1 did not alter brain ISF Aβ over 5 h, but longer-term effects of anti-Aβ antibodies on brain Aβ metabolism were not assessed; microdialysis may be insensitive to initial equilibrium changes.
- Stated/evident: LDLR overexpression was in neurons and astrocytes, not BBB cells, so the proposed LRP1/apoE cross-talk is speculative; the study is in mouse models, and a role for LDLR in cell-type-specific Aβ degradation could not be ruled out.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
11 Valid · 1 Not valid · 5 Not checked · 39 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These results suggest the LDLR overexpression in neurons and astrocytes (18) likely increases BBB-mediated Aβ clearance through an indirect mechanism involving other apoE receptors at the BBB, such as LRP1—a receptor shown to directly mediate Aβ clearance across the BBB (14, 15, 26).”
What the sources say
- Supportedcites [14] Deane R, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43:333–344. doi: 10.1016/j.neuron.2004.07.017. [DOI] [PubMed] [Google Scholar] source
The citation is attached to the assertion that LRP1 directly mediates Aβ clearance across the BBB, not to the proposed effect of LDLR overexpression in neurons and astrocytes. The Abstract reports a direct LRP/Aβ interaction on brain capillaries followed by Aβ endocytosis and transcytosis across the BBB. (LLM, conf=0.93)
- Supportedcites [15] Deane R, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002–4013. doi: 10.1172/JCI36663. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Introduction states that LRP1 is a major Aβ efflux transporter at the BBB and that Aβ binding to LRP1 initiates clearance from brain to blood. The citing authors’ proposed indirect effect of neuronal and astrocytic LDLR overexpression is their own inference; this source supports the cited point that LRP1 directly mediates BBB Aβ clearance. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [26] Yamada K, et al. The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid beta peptides in an in vitro model of the blood-brain barrier cells. J Biol Chem. 2008;283:34554–34562. doi: 10.1074/jbc.M801487200. [DOI] [PMC free article] [PubMed] [Google Scholar] source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“PDAPP mice have been previously reported to produce human APP/Aβ solely within the CNS (29, 30), allowing the fate of Aβ to be followed from brain into blood.”
What the sources say
- Not checked — no full text of the sourcecites [29] Johnson-Wood K, et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA. 1997;94:1550–1555. doi: 10.1073/pnas.94.4.1550. [DOI] [PMC free article] [PubMed] [Google Scholar] source
- Partly supportedcites [30] DeMattos RB, et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA. 2001;98:8850–8855. doi: 10.1073/pnas.151261398. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Abstract says PDAPP mice generate Aβ specifically within the CNS, supporting the claim about Aβ. The Results and Discussion qualify the broader statement: human APP and human Aβ are produced “almost solely” in the brain, not strictly solely there. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“our work strongly suggests that LDLR influences Aβ metabolism by affecting its clearance from the brain into blood, a mechanism previously suggested only for LRP1 and VLDLR (13–15, 26).”
What the sources say
- Supportedcites [13] Bell RD, et al. Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27:909–918. doi: 10.1038/sj.jcbfm.9600419. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The citation supports the sentence’s prior-mechanism clause, not the citing authors’ conclusion about LDLR. The Results report that intact Aβ reaches mouse plasma through LRP1-dependent efflux across the blood–brain barrier. The Discussion explicitly leaves LDLR’s possible role for future study. (LLM, conf=0.90)
- Supportedcites [14] Deane R, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43:333–344. doi: 10.1016/j.neuron.2004.07.017. [DOI] [PubMed] [Google Scholar] source
The citation supports the citing sentence’s background point about LRP1, not the citing authors’ own finding about LDLR. The source’s Discussion states that LRP clears soluble Aβ40 from brain interstitial fluid to blood; its Abstract identifies LRP-mediated transport across the blood-brain barrier. (LLM, conf=0.92)
- Supportedcites [15] Deane R, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002–4013. doi: 10.1172/JCI36663. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The citation supports the sentence’s historical comparison, not the citing authors’ own finding about LDLR. The Introduction states that LRP1 clears Aβ from brain to blood across the blood–brain barrier, and the Abstract describes VLDLR-mediated clearance of Aβ–apoE complexes. The source does not support LDLR as an Aβ efflux receptor, but the sentence does not attribute that finding to it. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [26] Yamada K, et al. The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid beta peptides in an in vitro model of the blood-brain barrier cells. J Biol Chem. 2008;283:34554–34562. doi: 10.1074/jbc.M801487200. [DOI] [PMC free article] [PubMed] [Google Scholar] source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Notably, the contribution of ISF bulk flow to total Aβ clearance was minimal (Fig. 1B), consistent with previous studies (14, 15, 20).”
What the sources say
- Could not verifycites [14] Deane R, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43:333–344. doi: 10.1016/j.neuron.2004.07.017. [DOI] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Results describe correcting Aβ transport rates for ISF bulk flow by subtracting inulin elimination. The clearance calculations likewise account for ISF flow, but the retrieved passages do not quantify its contribution to total Aβ clearance or say that it is minimal (searched: bulk flow, inulin clearance, minimal contribution). (LLM, conf=0.70)
- Partly supportedcites [15] Deane R, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002–4013. doi: 10.1172/JCI36663. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Results (page unavailable) describe ISF flow as slow for apoE isoforms, and Figure 3D compares ISF flow with other routes of Aβ clearance. The available text does not establish that ISF bulk flow makes a minimal contribution to total Aβ clearance, particularly across the Aβ forms and complexes studied. (LLM, conf=0.76)
- Supportedcites [20] Shibata M, et al. Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106:1489–1499. doi: 10.1172/JCI10498. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Results (p. 4) report that, over five hours at a 60 nM Aβ1-40 dose, ISF bulk flow accounted for 10.7% of the dose, compared with 73.8% transported across the BBB. This supports describing the ISF bulk-flow contribution as minimal in the studied conditions. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We did not observe any changes in APP expression or processing in brains of mice overexpressing LDLR (18); our work strongly suggests that LDLR influences Aβ metabolism by affecting its clearance from the brain into blood, a mechanism previously suggested only for LRP1 and VLDLR (13–15, 26).”
What the sources say
- Partly supportedcites [18] Kim J, et al. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 2009;64:632–644. doi: 10.1016/j.neuron.2009.11.013. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says APP processing was unlikely to be altered by LDLR overexpression because APP carboxyl-terminal fragment levels did not differ between genotypes. Our copy does not establish the separate claim that APP expression was unchanged. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
32 more claims · 3 with their cited sources checked
Create a free account to see all 56 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 11
- Probably not a substantial claim. 9
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“overexpression of LDLR is an effective approach to significantly induce apoE reduction and consequent alleviation of pathological changes in AD mouse models”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Castellano et al 2012
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Indeed, overexpression of Ldlr decreased both APOE and Aβ levels by enhancing Aβ clearance in amyloidosis mouse models. 16 , 18”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Overexpression of the low‐density lipoprotein receptor (LDLR) is known to decrease apolipoprotein E (APOE) levels and alleviate amyloid beta (Aβ) pathology.”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Of note, the overexpression of Ldlr significantly reduced APOE and Aβ levels in Aβ‐amyloidosis mouse models. 16 , 18”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“These findings underscore the critical role of LDLR in regulating Aβ accumulation and position it as a potential therapeutic target for AD.”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [18]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Discussion
“the HJ5.1 (anti-Aβ13–28) antibody”
§ Materials and Methods
“250 μg HJ5.1 (anti-Aβ17–28 antibody generated in-house)”
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703 · cited 2×
“Although LDLR is well-studied for its role in mediating removal of cholesterol and cholesterol esters in the periphery (35), little is known about its function in the CNS.”
BackgroundAstrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595 · cited 2×
“S2B), which labels microvessel abluminal surfaces at the astrocyte-vessel interface (24).”
BackgroundPericytes regulate the blood–brain barrier
Armulik, A., Genové, G., Mäe, M., Nisancioglu, M. H., Wallgard, E., Niaudet, C., He, L., Norlin, J., Lindblom, P., Strittmatter, K., et al. (2010) · Nature · doi:10.1038/nature09522 · Cited by 2,843 · cited 2×
“Given that haploinsufficiency of either apoE3 or apoE4 leads to reduced amyloid burden (25, 47), we would expect that reducing apoE levels by LDLR overexpression may result in enhanced Aβ clearance across the BBB in the context of either apoE3 or apoE4, and that increasing apoE expression would impair clearance.”
BackgroundDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962 · cited 2×
“Discussion The accumulation of Aβ into high-order species and amyloid plaques throughout life is hypothesized to be a critical initiating event in AD pathogenesis (2, 3, 33).”
BackgroundSchmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525 · cited 1×
“(2000) Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain”
BackgroundShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 2×
“(2000) Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain”
BackgroundResultSelf-citationDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Self-citationHuman ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 4×
“We recently provided in vivo evidence that human apoE isoforms differentially regulate soluble Aβ clearance from brain ISF (11, 15), with the slowest Aβ clearance observed in mice expressing APOE ε4 (11), the strongest identified genetic risk factor for AD (5).”
BackgroundMethodSelf-citation
Cited by
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
“transport (Castellano et al., 2012; Zlokovic, 2013), glymphatic clearance (Iliff et al.”
Self-citationThe Pathobiology of Vascular Dementia
Iadecola, C. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.008 · Cited by 1,857
APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches
Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30412-9 · Cited by 1,037
Nguyen, P. H., Ramamoorthy, A., Sahoo, B. R., Zheng, J., Faller, P., Straub, J. E., Dominguez, L., Shea, J.-E., Dokholyan, N. V., De Simone, A., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01122 · Cited by 678
ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?
Kanekiyo, T., Xu, H., & Bu, G. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.045 · Cited by 608
Metadata
- Authors
- Castellano, J. M., Deane, R., Gottesdiener, A. J., Verghese, P. B., Stewart, F. R., West, T., Paoletti, A. C., Kasper, T. R., DeMattos, R. B., Zlokovic, B. V., & Holtzman, D. M.
- Affiliations
- Washington University in St. Louis (US)
- University of Rochester Medicine (US)
- Hope Center for Neurological Disorders (US)
- C2N Diagnostics (United States) (US)
- Eli Lilly (United States) (US)
- Department of Physiology and Biophysics, Zilkha Neurogenetic Institute, University of Southern California Keck School of Medicine, Los Angeles, CA 90089
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2012-08-27
- Volume
- 109
- Issue
- 38
- Pages
- 15502-15507
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3458349
- OpenAlex
- W2017624892
- Cited by
- 154
- References
- 51
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 8 · 2023: 6 · 2022: 16 · 2021: 11 · 2020: 10 · 2019: 12 · 2018: 3 · 2017: 10 · 2016: 11 · 2015: 15 · 2014: 29 · 2013: 14
- FWCI
- 12.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p30ns069329-02)
- National Institute on Aging (R01AG023084, R01AG013956, R37AG023084, F31AG034004, R01AG035083, AG029481, AG034004, R01AG029481, P50AG005681, P01AG003991, R37AG013956, AG13956, K23AG030946, AG023084, P01AG026276, U24AG021886)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK056341)
- National Institute of Neurological Disorders and Stroke (P30-NS069329, NS034467, R37NS034467, P30NS057105, NS34467, R01NS034467)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- LDL receptor, amyloid-beta clearance, blood-brain barrier, Alzheimer's disease, APOE ε4, brain interstitial fluid, amyloid plaques, anti-amyloid antibodies, apoE receptors
- MeSH terms
- Alleles, Amyloidosis, Animals, Blood-Brain Barrier, Brain, Disease Models, Animal, Insulin, Kinetics, Mice, Inbred C57BL, Mice, Inbred DBA, Mice, Transgenic, Receptors, LDL, Amyloid beta-Peptides, Microdialysis, Transgenes, Mice, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. https://app.cochat.ai/papers/10.1073/pnas.1206446109
- The paper
- Castellano, J. M., Deane, R., Gottesdiener, A. J., Verghese, P. B., Stewart, F. R., West, T., Paoletti, A. C., Kasper, T. R., DeMattos, R. B., Zlokovic, B. V., & Holtzman, D. M. (2012). Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1206446109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.